Eli Lilly will soon release key data on its weight loss pill. Here's why it could be a game-changer

• Here’s why Ozempic maker’s new weight-loss drug isn’t good enough for investors

  New trial data showed CagriSema led to “superior” weight loss, but at a rate much less than original expectations of 25%.
  
  MarketWatch - Mar. 10

• Novo Nordisk shares fall 6.3% after latest trial results for its next-generation weight loss drug

  Shares of Novo Nordisk fell sharply on Monday, after the firm published results from the latest clinical trial of its CagriSema weight-loss drug.
  
  CNBC - Mar. 10

• Healthy Returns: Novo Nordisk scoops up Chinese obesity drug to compete with Eli Lilly

  Novo Nordisk is taking aim at Eli Lilly with a new obesity drug deal. Meanwhile, a survey shows doctors' perception of the health care system is improving.
  
  CNBC - 7h
• 

  Novo Nordisk shares fall on latest trial results for new obesity drug

  Participants with type 2 diabetes had an average weight loss of 15.7 per cent after 68 weeks on CagriSema
  
  Financial Times - Mar. 10

• The market comeback continues — plus, a key catalyst is on the horizon for Eli Lilly

  Every weekday, the Investing Club releases the Homestretch; an actionable afternoon update just in time for the last hour of trading.
  
  CNBC - 1d

• Why a weight-loss drug could become a geopolitical bargaining chip

  Ozempic might feature in US negotiations with Denmark over Greenland
  
  Financial Times - 4d

• Roche takes big step in weight-loss field with $5.3 billion deal. Novo Nordisk shares fall.

  Swiss drugmaker Roche on Wednesday announced a major deal in the weight-loss category, agreeing to pay up to $5.3 billion to Zealand Pharma in a licensing and development deal.
  
  MarketWatch - Mar. 12

• Zepbound copycats remain online despite FDA ban

  Copycat versions of Eli Lilly's diabetes drug Mounjaro and obesity drug Zepbound were supposed to go away this week. They're still available on some websites.
  
  CNBC - 3d

• Brentford captain feared sleeping pill addiction

  Brentford captain Christian Nørgaard has said he feared becoming addicted to sleeping pills after taking the medication to prepare for away games.
  
  ESPN - Mar. 14

More from CNBC

• Chinese EV giant BYD outpaces Tesla with annual sales of more than $100 billion

  China's BYD reported annual revenue of 777 billion yuan ($107 billion) for 2024, leapfrogging Tesla as competition between the two EV rivals heats up.
  
  CNBC - 9h

• Recession is coming before end of 2025, generally 'pessimistic' corporate CFOs say: CNBC survey

  The US economy will enter a recession in 2025, with Trump's tariffs leading top corporate CFOs to 'pessimism' and less spending, according to a CNBC survey.
  
  CNBC - 10h

• With 23andMe entering bankruptcy, here's how to delete your genetic data

  Now that 23andMe has filed for bankruptcy, another company could take control of its genetic database.
  
  CNBC - 43m

• Consumer confidence in where the economy is headed hits 12-year low

  Consumer confidence dimmed further in March as the view of future conditions fell to the lowest level in more than a decade.
  
  CNBC - 3h

• Google quantum exec says tech is '5 years out from a real breakout'

  Julian Kelly, Google Quantum AI's director of hardware, told CNBC quantum computers may only be about five years from a breakthrough.
  
  CNBC - 1h

More in Business

• 

  U.S. Adds Export Restrictions to More Chinese Tech Firms Over Security Concerns

  The additions included companies that are customers of Intel and Nvidia, and one firm that was the focus of a New York Times investigation last year.
  
  The New York Times - 21m
• 

  US proposes new critical minerals deal to Ukraine, says Zelenskyy

  Kyiv says Washington’s proposal would be ‘grand agreement’ but does not include taking over nuclear power plants
  
  Financial Times - 37m

• With 23andMe entering bankruptcy, here's how to delete your genetic data

  Now that 23andMe has filed for bankruptcy, another company could take control of its genetic database.
  
  CNBC - 43m

• Google quantum exec says tech is '5 years out from a real breakout'

  Julian Kelly, Google Quantum AI's director of hardware, told CNBC quantum computers may only be about five years from a breakthrough.
  
  CNBC - 1h
• 

  Reeves to unveil £2.2bn UK defence spending boost in Spring Statement

  Chancellor seeks new cuts in Whitehall after UK fiscal watchdog questions size of planned savings on welfare
  
  Financial Times - 1h